Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study
Hämostaseologie · 29.07.2026
DOI: 10.1055/a-2918-8110 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Hämostaseologie, erschienen am 29.07.2026. Verfasst von Lukas Röthlisberger und 2 weiteren Autor:innen. Beteiligte Einrichtung: University Children's Hospital Zürich, Department of Haematology, ZH, Switzerland, Zürich.
Abstract (Originalsprache)
Background
Direct oral anticoagulants (DOACs) show increasing popularity in the treatment of paediatric venous thromboembolism (VTE), but real-world evidence outside clinical trials remains scarce.
Objectives
This study aimed to evaluate the use, safety and effectiveness of rivaroxaban in a real-world paediatric cohort at a tertiary care hospital.
Methods
All children exposed to rivaroxaban between January 2020 and June 2025 at our institution were included into this single-centre retrospective cohort study. In chart reviews, effectiveness was assessed as thrombus recurrence, progression, resolution, or improvement; safety outcomes included clinically relevant bleeding (CRB) and minor bleeding.
Results
Fifty-seven children were included at a median age of 13.8 years (IQR 7.1–15.6); 49% were female. In the treatment group (n = 37), one thrombosis recurred (3%), with thrombus resolution in 19 (54%) and radiologic improvement in 5 patients (14%). In the prophylaxis group (n = 20), no incident VTE occurred. Overall, CRB was rare (7%), all non-major during rivaroxaban exposure and occurred exclusively in children with identifiable additional bleeding risk factors.
Conclusions
Rivaroxaban demonstrated a favourable effectiveness and safety profile in this real-world paediatric cohort, with outcomes comparable to available real-world and trial data. CRB events clustered in settings with additional bleeding risks, underscoring the importance of patient characteristics in guiding therapy. Our findings support rivaroxaban as a feasible anticoagulation option in children.
Autor:innen und Institutionen
- University Children's Hospital Zürich, Department of Haematology, ZH, Switzerland, Zürich.
- University of Zurich, Faculty of Medicine, ZH, Switzerland, Zürich.
ORCID-Profile: Alessandra Bosch
Zitieren
APA
Röthlisberger, L., Albisetti, M., & Bosch, A. (2026). Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study. Hämostaseologie. https://doi.org/10.1055/a-2918-8110
Vancouver
Röthlisberger L, Albisetti M, Bosch A. Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study. Hämostaseologie. 2026. doi:10.1055/a-2918-8110
BibTeX
@article{Rthlisberger2026,
author = {Röthlisberger, Lukas and Albisetti, Manuela and Bosch, Alessandra},
title = {Rivaroxaban in Paediatric Patients Beyond Clinical Trial Settings – A Real-World Retrospective Cohort Study},
journal = {Hämostaseologie},
year = {2026},
doi = {10.1055/a-2918-8110}
}
EUVIMED